Kyntra Bio Q2 2026 net income $12M vs year-ago loss; cash $95.7M, runway to 2028

KYNTRA BIO, INC.

Net income from continuing ops $12.0M ($2.96/share) vs net loss $13.7M ($3.38/share) in Q2 2025.
Total revenue from continuing ops was negative $1.5M vs positive $1.3M in Q2 2025.
Cash, cash equivalents, investments, and accounts receivable $95.7M as of June 30, 2026; expected to fund operations into 2028.
FG-3246 Phase 2 interim analysis in mCRPC on track for 4Q 2026; roxadustat Phase 3 protocol finalized, initiation targeted 4Q 2026.
New MATTERHORN post hoc data at EHA 2026 showed transfusion independence benefit in LR-MDS with HTB.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.